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Results: Taxotere could inhibit the proliferation of A549 cell by a 
time and dose-dependent manner and the combination with Celecoxib 
(12.5µmol/l, 25µmol/l) could improve the inhibition. After 48h of incu-
bation with Taxotere, the highest inhibitory rate of the cell is 65% and 
the lowest inhibitory rate is 10%. High-dose celecoxib (>50µmol/l) can 
suppress COX-2 gene expression, while positive response was found 
in low-dose celecoxib(12.5µmol/l,25µmol/l) and the combination. 
Celecoxib can increase the percentage of cell in G0/G1 and decrease 
that in S and G2/M. The apoptosis rate of cell increased after Celecoxib 
combined with Taxotere. 
Conclusion: Taxotere could inhibit effectively the growth of A549 cell 
lines in vitro and the combination with Celecoxib could improve the 
inhibition through induceing apopotosis and inﬂuencing the distribu-
tion of cell cycle, but had no signiﬁcant inﬂuence in the expression of 
COX-2 protein.
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A phase II trial of pemetrexed in non-small cell lung cancer 
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Background: Pemetrexed is an effective salvage agent in NSCLC 
patients failing previous chemotherapy. Our aim was to evaluate the 
efﬁcacy of pemetrexed in Chinese NSCLC patients who had failed 
previous platinum-based chemotherapy and had been salvaged with 
tyrosine-kinase inhibitor (TKI) treatment or not. 
Methods: Treatment consisted of pemetrexed 500 mg/m2 intravenous 
infusion on day 1 of every 3 weeks. Standard premedications, including 
vitamin B12, folic acid, and dexamethasone were given.
Results: Between June 2005 and November 2006, 44 patients (pts) 
were enrolled and completed the study. All had been treated with 
platinum-based chemotherapy. Thirty patients had been treated with 
TKI after they failed platinum-based chemotherapy. The present treat-
ment was second-line treatment in 10 pts, and third-line or higher in 
34 pts. Mean age was 62. Median cycles received was 4, and objective 
response rates was 18.2% (8 pts had PR). Treatment-related toxicities 
were mild and few. Grade 3 or 4 haematological toxicities included 
neutropenia in 18.2%, thrombocytopenia in 6.8%, and anemia in 4.5 
pts. Non-haematological toxicities were all less than grade 3. Median 
time to disease progression was 4.4 months and median survival was 
9.1 months. Those received present treatment as second line treat-
ment had a better response than as third line or later treatment (40% 
vs. 11.8%, p=0.043). Previous treatment with TKI or not did not affect 
patient’s response to present treatment (p=0.782) 
Conclusions: This study demonstrated that pemetrexed salvage chemo-
therapy in NSCLC patients who have failed previous platinum-based 
chemotherapy produces a relatively lower toxicity proﬁle, and a better 
compliance and response rate than conventional salvage chemotherapy. 
Use of pemetrexed as second line agent will have better response rate 
than as third line or later treatment. 
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Background: Our aim here was to determine whether or not add-
ing cisplatin into vinorelbine treatment is an appropriate regimen for 
chemo-naïve NSCLC in patients aged 70 or older.
Methods: After stratiﬁcation by performance status, patients were 
randomized into vinorelbine (V) or vinorelbine plus cisplatin (VP) 
treatment arms. Treatment consisted of vinorelbine 25 mg/m2 intrave-
nous infusion on days 1 and 8 of every 3 weeks (V arm), or vinorelbine 
22.5 mg/m2 intravenous infusion on days 1 and 8, and cisplatin 60 
mg/m2 intravenous infusion on day 1 of every 3 weeks (VP arm). From 
May 2005 to December 2006, 68 patients were enrolled. Sixty-three 
patients went off-study before end of February 2007. Present analysis 
was based on these 63 patients.
Results: There were 29 patients received V treatment and 34 patients 
received VP treatment. There was no statistical signiﬁcant difference in 
clinical characteristics. In all, 104 cycles of V (median, 4 cycles per pa-
tient) and 137 cycles of VP (median, 4 cycles per patient) were given. 
Objective response rates were 17.2% in V and 32.4% in VP (p=0.175). 
Control rates were 51.7% in V and 82.4% in VP (p=0.009). Myelo-
suppression was more common and severe in VP arm. Any grade of 
anemia and neutropenia were signiﬁcantly higher in VP arm (p=0.002 
and 0.018, respectively). Two patients in VP arm suffered from febrile 
neutropenia and one patient died in spite of G-CSF and antibiotic 
treatment. There was only one patient in V arm who had uneventful 
febrile neutropenia. Non-haematological toxicities was mild and all less 
than grade 3, except one patient in VP arm who suffered from grade 3 
renal function impairment and one patient in V arm who had grade 3 
phlebitis. Fatigue sensation was more common and severe in VP arm 
(p=0.031). Median time to disease progression was 2.7 months in V 
arm and 5.2 months in VP arm (p=0.0125). One-year survival rate was 
49.8% in V arm and 45.4% in VP arm.
Conclusions: Adding cisplatin into vinorelbine treatment is feasible in 
elderly patients, and has better disease control rate and longer me-
dian time to disease progression. However, vinorelbine plus cisplatin 
treatment was more toxic than vinorelbine treatment alone in elderly 
patients.
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The effects of NSCLC neoadjuvant therapy on the serum and 
tumor levels of growth factors, apoptosis and invasiveness markers
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Our aim was to evaluate the effect of neoadjuvant therapy and subse-
quent surgical treatment of non-small cell lung cancer (NSCLC) on 
serum markers of tumor growth and expansion: VEGF, TGF-β, bFGF, 
TIMP-1 and apoptosis marker CD95L assessed by Elisa. 24 NSCLC 
patients were evaluated: 12 in stage IIIA. 9-IIB,1-IIA, 1-IB, 1-IA. 
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Considerable decrease of TGF-β (p<<0,01), VEGF (p<0,01) and bFGF 
(p<<0,01) in serum was observed following neoadjuvant therapy, with 
no signiﬁcant changes in TIMP-1 and CD95L levels. In serum samples 
collected directly after tumor resection signiﬁcant drop-down of bFGF 
(p<<0,001) continued, while VEGF levels increased (p<0,001), TGF- β 
levels didn’t change and continued to be lower than before therapy 
(p<0,01). As previously, tumor resection didn’t affect TIMP-1 and 
CD95L. Serum levels of VEGF and CD95L as well as CD95L and 
TIMP-1 correlated well before (r=0,36, p<0,05 and r=0,48, p<0,001) 
and after (r=0,35;r=0,39, p<0,05) neoadjuvant therapy. Similar rela-
tion was observed for TGF-βand ﬁbrinogen as well as ﬁbrinogen and 
TIMP-1 before (r=0,499;r=0,41 p<<0,01) and after (r=-0,44;r=0,40, 
p<0,01) surgery. As expected levels of TGF- β, TIMP-1 and bFGF 
were signiﬁcantly higher in excissed tumor than in normal lung tissue 
(p<0,001), while no differences in VEGF and CD95L content were 
demonstrated. Neoadjuvant therapy considerably affected cytokines 
regulating tumor growth: VEGF, bFGF, TGF-β while serum markers 
of apoptosis CD95L or local tumour invasiveness TIMP-1 were not 
affected. Postoperative changes of growth factors might be due to the 
tumor resection and wound healing. 
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What is the standard platinium-derivative based-chemotherapy 
for advanced or metastatic NSCLC: a 10-years trial comparing 
cisplatin (C) and carboplatin (Ca) in combination with gemcitabine 
(G)
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Objectives: to compare survival results obtained at our unit during a 
10-year-time period (1997-2006) with the combinations CG and CaG 
in the treatment of advanced NSCLC patients (pts), and try to answer 
some doubts concerning the balance between efﬁcacy (response and 
survival) and toxicity of these two combinations.
Patients and Methods: 608 pts (stage IIIB -282 IV- 324 were treated 
in this period (CG - 305; CaG - 303). Treatment schedules were: CG (C 
- 80 mg/m2 d1 + G 1000mg d1 and 8 each 3 weeks); CaG (Ca - AUC 
5 d1 + G - 1000mg/m2 d1 and 8 each 3 weeks). Groups were well bal-
anced in which concerns all signiﬁcant prognostic factors to survival.
Baseline and pos-CT characteristics were compared between groups 
using a 2-way-Anova analysis, OOR response rate and toxicities were 
compared with Fisher’s exact test; in order to compare survival curves 
and to estimate hazard ratios and respective CI we used a Cox propor-
tional hazards model stratiﬁed for stage and adjusted for prognostic 
variables.
Results: With a median follow-up of 61 months, more than 88% were 
uncensored (85% for CG and 90% for CaG), OOR is higher for CG 
(41.8% - 95%CI 34.9- 51.1) than for CaG (29.4% - 95%CI 23.2-35.6 
p=0.0034). This clinical response is in line with Cyfra 21-1 median 
drop (-32.7% for CG and - 7.1% for CaG p=0.0028). Comparison of 
median survival beneﬁts CG (overall 10.2 vs. 8.1 mo p=.00006; stage 
IIIB 14.2 vs. 9.9 p=.00029; stage IV 9.6 vs. 7.7 p=0.022). Differences 
in IFD were even more signiﬁcant (overall - CG 6.2 mo vs. CaG 4.3 
p<.000001.) Survival-rates were similarly higher for CG. Haematologi-
cal toxicity was similar for both treatments with the exception of an 
excess of grade 3 and 4 thrombocytopenia for CaG. Few signiﬁcant 
non-haematological side effects were detected. Seven toxic deaths (3 
CG and 4 CaG were reported).
Conclusions: the result of our 10-year study makes clear that CG 
combination is more effective than CaG in which concerns response 
rate, IFD and survival. Haematological toxicity is similar between 
groups, except for thrombocytopenia, more frequent with carboplatin-
based chemotherapy. Consistency of results (response, decrease of 
serum cyfra 21-1 and survival) obtained with the CG association in this 
10-year study together with moderate toxicity, points clearly to this CT 
treatment as the standard for pts with advanced or metastatic NSCLC.
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Non-small cell lung cancer (NSCLC) is the leading cause of cancer 
mortality for men and women in the United States. More effective 
treatments are needed to prolong survival and improve quality of 
life. Platin-containing chemotherapy doublets are commonly used in 
NSCLC treatment. ABT-751 is a novel oral anti-microtubule agent 
targeting the colchicine binding site. As single agent, it was well-toler-
ated and showed a preliminary signal of activity in previously treated 
NSCLC. In vivo studies demonstrated additive activity between ABT-
751 and cisplatin in a NSCLC xenograft model.
A phase I trial of ABT-751 and carboplatin was conducted in patients 
with advanced previously treated NSCLC. Primary objective was to 
determine the maximum tolerated dose (MTD). Secondary objec-
tives were evaluation of toxicities, efﬁcacy, and surrogate markers of 
response (cell cycle changes and cyclin D1 expression) in buccal swabs 
from patients at the phase II dose. Four dose levels were studied - 1: 
ABT-751 100 mg bid, carboplatin AUC 4.5; 2: ABT-751 125 mg bid, 
carboplatin AUC 4.5; 3: ABT-751 125 mg bid, carboplatin AUC 6; 4: 
ABT-751 150 mg bid, carboplatin AUC 6. ABT-751 was taken orally 
twice a day for 7 days in a 21-day cycle, carboplatin was administered 
intravenously on day 4 during cycle 1 to allow for pharmacokinetic 
analysis, and on day 1 of subsequent cycles. Rapid dose escalation was 
used for the ﬁrst 3 dose levels followed by cohorts of at least 3 patients 
for the remaining dose levels.
Thirteen patients were enrolled, twelve patients completed one cycle of 
therapy and were evaluable for toxicities. All patients were previously 
treated with a carboplatin-containing regimen. All patients had stage IV 
NSCLC, median age was 62 years (range 46-73), 5 were women, 2 pa-
tients had Karnofsky performance score (KPS) 90, the rest had KPS 80. 
Seven patients had one and 5 patients had 2 prior therapies. A median 
of 2.5 (1-4) cycles was administered. Dose-limiting toxicities (DLTs) 
were assessed at the end of cycle one. Grade 3 fatigue and grade 4 
thrombocytopenia and neutropenia were observed in 2/5 patients 
on dose level 4. Common grade 2 toxicities were constipation and 
peripheral sensory neuropathy (levels 2-4). MTD was dose level 3. Ten 
patients were evaluable for response, 2 had partial responses lasting 14 
and 28 weeks (levels 2 and 4, both had one prior therapy), 4 had stable 
disease, 4 had disease progression. Median time to progression was 13 
